Velusetrag: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|A medication used for the treatment of gastrointestinal disorders}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Velusetrag_structure.svg | |||
| image2 = Velusetrag2.png | |||
}} | |||
'''Velusetrag''' is a medication that acts as an agonist of the [[5-HT4 receptor]], which is a subtype of the [[serotonin receptor]]. It is primarily used in the treatment of certain [[gastrointestinal disorders]], particularly those involving [[motility]] issues. | |||
Velusetrag | |||
== Mechanism of Action == | ==Mechanism of Action== | ||
Velusetrag works by stimulating the | Velusetrag works by stimulating the 5-HT4 receptors in the [[gastrointestinal tract]]. This action enhances the release of [[acetylcholine]], a neurotransmitter that promotes [[peristalsis]] and increases [[gastrointestinal motility]]. By activating these receptors, Velusetrag helps to alleviate symptoms associated with conditions like [[chronic idiopathic constipation]] and [[gastroparesis]]. | ||
== Clinical | ==Clinical Uses== | ||
Velusetrag | Velusetrag is primarily indicated for the treatment of chronic idiopathic constipation. It has been studied for its potential benefits in other motility disorders, such as gastroparesis, where delayed gastric emptying is a significant concern. Clinical trials have demonstrated its efficacy in improving bowel movement frequency and reducing associated symptoms. | ||
== Side Effects == | ==Side Effects== | ||
Common side effects of Velusetrag include [[ | Common side effects of Velusetrag include [[headache]], [[nausea]], and [[diarrhea]]. These effects are generally mild to moderate in severity. As with any medication, there is a potential for more serious adverse effects, and patients are advised to consult their healthcare provider if they experience any unusual symptoms. | ||
== | ==Pharmacokinetics== | ||
Velusetrag is administered orally and is well absorbed in the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily in the urine. The pharmacokinetic profile of Velusetrag supports its use as a once-daily medication, which can improve patient compliance. | |||
[[ | ==Research and Development== | ||
[[Category: | Velusetrag was developed as part of ongoing research into 5-HT4 receptor agonists, which have shown promise in treating various gastrointestinal disorders. The development of Velusetrag involved extensive clinical trials to establish its safety and efficacy profile. | ||
==Related Pages== | |||
* [[Serotonin receptor]] | |||
* [[Gastrointestinal motility]] | |||
* [[Chronic idiopathic constipation]] | |||
* [[Gastroparesis]] | |||
==References== | |||
{{Reflist}} | |||
[[Category:5-HT4 agonists]] | |||
[[Category:Gastrointestinal drugs]] | [[Category:Gastrointestinal drugs]] | ||
<gallery> | |||
File:Velusetrag_structure.svg|Structure of Velusetrag | |||
File:Velusetrag2.png|Another view of Velusetrag | |||
</gallery> | |||
Latest revision as of 02:05, 17 February 2025
A medication used for the treatment of gastrointestinal disorders
| Velusetrag | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Velusetrag is a medication that acts as an agonist of the 5-HT4 receptor, which is a subtype of the serotonin receptor. It is primarily used in the treatment of certain gastrointestinal disorders, particularly those involving motility issues.
Mechanism of Action[edit]
Velusetrag works by stimulating the 5-HT4 receptors in the gastrointestinal tract. This action enhances the release of acetylcholine, a neurotransmitter that promotes peristalsis and increases gastrointestinal motility. By activating these receptors, Velusetrag helps to alleviate symptoms associated with conditions like chronic idiopathic constipation and gastroparesis.
Clinical Uses[edit]
Velusetrag is primarily indicated for the treatment of chronic idiopathic constipation. It has been studied for its potential benefits in other motility disorders, such as gastroparesis, where delayed gastric emptying is a significant concern. Clinical trials have demonstrated its efficacy in improving bowel movement frequency and reducing associated symptoms.
Side Effects[edit]
Common side effects of Velusetrag include headache, nausea, and diarrhea. These effects are generally mild to moderate in severity. As with any medication, there is a potential for more serious adverse effects, and patients are advised to consult their healthcare provider if they experience any unusual symptoms.
Pharmacokinetics[edit]
Velusetrag is administered orally and is well absorbed in the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily in the urine. The pharmacokinetic profile of Velusetrag supports its use as a once-daily medication, which can improve patient compliance.
Research and Development[edit]
Velusetrag was developed as part of ongoing research into 5-HT4 receptor agonists, which have shown promise in treating various gastrointestinal disorders. The development of Velusetrag involved extensive clinical trials to establish its safety and efficacy profile.
Related Pages[edit]
References[edit]
<references group="" responsive="1"></references>
-
Structure of Velusetrag -
Another view of Velusetrag
